Algert Global LLC decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 54.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,625 shares of the company's stock after selling 32,223 shares during the period. Algert Global LLC owned approximately 0.06% of Pacira BioSciences worth $502,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC acquired a new stake in Pacira BioSciences in the fourth quarter valued at about $26,000. Caitlin John LLC lifted its position in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its position in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.
Pacira BioSciences Trading Up 0.8%
Shares of Pacira BioSciences stock opened at $25.12 on Monday. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.16 billion, a PE ratio of -12.37 and a beta of 0.56. The company has a 50-day moving average of $24.73 and a two-hundred day moving average of $22.17.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays raised their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Finally, HC Wainwright raised their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $26.44.
Get Our Latest Stock Analysis on Pacira BioSciences
About Pacira BioSciences
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
See Also
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
